739 related articles for article (PubMed ID: 10859028)
1. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo.
Takeuchi M; Makita Z; Bucala R; Suzuki T; Koike T; Kameda Y
Mol Med; 2000 Feb; 6(2):114-25. PubMed ID: 10859028
[TBL] [Abstract][Full Text] [Related]
2. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients.
Takeuchi M; Makita Z; Yanagisawa K; Kameda Y; Koike T
Mol Med; 1999 Jun; 5(6):393-405. PubMed ID: 10415164
[TBL] [Abstract][Full Text] [Related]
3. Immunological detection of a novel advanced glycation end-product.
Takeuchi M; Yanase Y; Matsuura N; Yamagishi Si S; Kameda Y; Bucala R; Makita Z
Mol Med; 2001 Nov; 7(11):783-91. PubMed ID: 11788793
[TBL] [Abstract][Full Text] [Related]
4. Maillard reactions by alpha-oxoaldehydes: detection of glyoxal-modified proteins.
Sady C; Jiang CL; Chellan P; Madhun Z; Duve Y; Glomb MA; Nagaraj RH
Biochim Biophys Acta; 2000 Sep; 1481(2):255-64. PubMed ID: 11018716
[TBL] [Abstract][Full Text] [Related]
5. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins.
Reddy S; Bichler J; Wells-Knecht KJ; Thorpe SR; Baynes JW
Biochemistry; 1995 Aug; 34(34):10872-8. PubMed ID: 7662668
[TBL] [Abstract][Full Text] [Related]
6. Alternative routes for the formation of immunochemically distinct advanced glycation end-products in vivo.
Takeuchi M; Makita Z
Curr Mol Med; 2001 Jul; 1(3):305-15. PubMed ID: 11899079
[TBL] [Abstract][Full Text] [Related]
7. Immunological detection of fructose-derived advanced glycation end-products.
Takeuchi M; Iwaki M; Takino J; Shirai H; Kawakami M; Bucala R; Yamagishi S
Lab Invest; 2010 Jul; 90(7):1117-27. PubMed ID: 20212455
[TBL] [Abstract][Full Text] [Related]
8. Glycolaldehyde, a reactive intermediate for advanced glycation end products, plays an important role in the generation of an active ligand for the macrophage scavenger receptor.
Nagai R; Matsumoto K; Ling X; Suzuki H; Araki T; Horiuchi S
Diabetes; 2000 Oct; 49(10):1714-23. PubMed ID: 11016456
[TBL] [Abstract][Full Text] [Related]
9. Autoantibody against N(epsilon)-(carboxymethyl)lysine: an advanced glycation end product of the Maillard reaction.
Shibayama R; Araki N; Nagai R; Horiuchi S
Diabetes; 1999 Sep; 48(9):1842-9. PubMed ID: 10480617
[TBL] [Abstract][Full Text] [Related]
10. Immunological evidence for methylglyoxal-derived modifications in vivo. Determination of antigenic epitopes.
Shamsi FA; Partal A; Sady C; Glomb MA; Nagaraj RH
J Biol Chem; 1998 Mar; 273(12):6928-36. PubMed ID: 9506998
[TBL] [Abstract][Full Text] [Related]
11. N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction.
Ikeda K; Higashi T; Sano H; Jinnouchi Y; Yoshida M; Araki T; Ueda S; Horiuchi S
Biochemistry; 1996 Jun; 35(24):8075-83. PubMed ID: 8672512
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction.
Glomb MA; Monnier VM
J Biol Chem; 1995 Apr; 270(17):10017-26. PubMed ID: 7730303
[TBL] [Abstract][Full Text] [Related]
13. Advanced glycation endproducts in food and their effects on health.
Poulsen MW; Hedegaard RV; Andersen JM; de Courten B; Bügel S; Nielsen J; Skibsted LH; Dragsted LO
Food Chem Toxicol; 2013 Oct; 60():10-37. PubMed ID: 23867544
[TBL] [Abstract][Full Text] [Related]
14. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation.
Ruggiero-Lopez D; Lecomte M; Moinet G; Patereau G; Lagarde M; Wiernsperger N
Biochem Pharmacol; 1999 Dec; 58(11):1765-73. PubMed ID: 10571251
[TBL] [Abstract][Full Text] [Related]
15. New biomarkers of Maillard reaction damage to proteins.
Wells-Knecht KJ; Brinkmann E; Wells-Knecht MC; Litchfield JE; Ahmed MU; Reddy S; Zyzak DV; Thorpe SR; Baynes JW
Nephrol Dial Transplant; 1996; 11 Suppl 5():41-7. PubMed ID: 9044306
[TBL] [Abstract][Full Text] [Related]
16. Impact of free N
Holik AK; Stöger V; Hölz K; Somoza MM; Somoza V
Food Funct; 2018 Jul; 9(7):3906-3915. PubMed ID: 29972203
[TBL] [Abstract][Full Text] [Related]
17. Identification of N epsilon-(carboxyethyl)lysine, one of the methylglyoxal-derived AGE structures, in glucose-modified protein: mechanism for protein modification by reactive aldehydes.
Nagai R; Araki T; Hayashi CM; Hayase F; Horiuchi S
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 May; 788(1):75-84. PubMed ID: 12668073
[TBL] [Abstract][Full Text] [Related]
18. Protein glycation: creation of catalytic sites for free radical generation.
Yim MB; Yim HS; Lee C; Kang SO; Chock PB
Ann N Y Acad Sci; 2001 Apr; 928():48-53. PubMed ID: 11795527
[TBL] [Abstract][Full Text] [Related]
19. Immunochemical detection of Nepsilon-(carboxyethyl)lysine using a specific antibody.
Nagai R; Fujiwara Y; Mera K; Yamagata K; Sakashita N; Takeya M
J Immunol Methods; 2008 Mar; 332(1-2):112-20. PubMed ID: 18242632
[TBL] [Abstract][Full Text] [Related]
20. Conventional antibody against Nepsilon-(carboxymethyl)lysine (CML) shows cross-reaction to Nepsilon-(carboxyethyl)lysine (CEL): immunochemical quantification of CML with a specific antibody.
Koito W; Araki T; Horiuchi S; Nagai R
J Biochem; 2004 Dec; 136(6):831-7. PubMed ID: 15671494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
